These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6139845)

  • 21. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurophysiological approach.
    Baribeau J; Laurent JP; Décary A
    Brain Cogn; 1993 Sep; 23(1):40-55. PubMed ID: 8105821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Visual and motor functions in schizophrenic patients].
    Del Vecchio S; Gargiulo PA
    Acta Psiquiatr Psicol Am Lat; 1992 Dec; 38(4):317-22. PubMed ID: 1364126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of schizophrenia: what the family doctor should know].
    Gruber O; Falkai P
    MMW Fortschr Med; 2008 May; 150 Suppl 2():16-9; quiz 20. PubMed ID: 18680837
    [No Abstract]   [Full Text] [Related]  

  • 26. [Neuroleptic treatment by the established psychiatrist. A report of experiences].
    Haberfellner EM; Rittmannsberger H
    Psychiatr Prax; 1998 Nov; 25(6):284-5. PubMed ID: 9885840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuroleptic malignant syndrome. Case reports].
    Berardi D; Troia M; Veronesi L; Ferrari G
    Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
    Himelhoch S; Taylor SF; Goldman RS; Tandon R
    Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
    [No Abstract]   [Full Text] [Related]  

  • 29. [Neuroleptic treatment and neurological soft signs in schizophrenic patients].
    Mechri A; Slama H; Chebel S; Mandhouj O; Gaha L
    Therapie; 2007; 62(5):449-53. PubMed ID: 18206107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients.
    Balestrieri M; Giaroli G; Mazzi M; Bellantuono C
    Pharmacopsychiatry; 2006 May; 39(3):81-4. PubMed ID: 16721695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients.
    Dagtekin O; Gerbershagen HJ; Wagner W; Petzke F; Radbruch L; Sabatowski R
    Anesth Analg; 2007 Nov; 105(5):1442-8, table of contents. PubMed ID: 17959980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients. Results from an experimental study.
    Kagerer S; Winter C; Möller HJ; Soyka M
    Neuropsychobiology; 2003; 47(4):212-8. PubMed ID: 12824745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotine reduces antisaccade errors in task impaired schizophrenic subjects.
    Larrison-Faucher AL; Matorin AA; Sereno AB
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):505-16. PubMed ID: 15093958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.
    Caligiuri MP; Teulings HL; Filoteo JV; Song D; Lohr JB
    Hum Mov Sci; 2006 Oct; 25(4-5):510-22. PubMed ID: 16647772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Weight gain and clozapine].
    Jalenques I; Tauveron I; Albuisson E; Audy V
    Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term neuroleptic treatment. Benefits and risks. Proceedings from a workshop, Copenhagen, 6th-7th September, 1979.
    Acta Psychiatr Scand Suppl; 1981; 291():1-159. PubMed ID: 6113728
    [No Abstract]   [Full Text] [Related]  

  • 38. The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.
    Manos N; Gkiouzepas J; Logothetis J
    Am J Psychiatry; 1981 Feb; 138(2):184-8. PubMed ID: 6109453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oral glucose tolerance test in schizophrenics under long-term neuroleptic treatment (author's transl)].
    Gonçalves N; Grüneberg F
    Pharmakopsychiatr Neuropsychopharmakol; 1975 Sep; 8(5):289-95. PubMed ID: 1233523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The handwriting test as an aid to neuroleptic dosage.
    Küstner U; Müller-Oerlinghausen B
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S34-41. PubMed ID: 2878893
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.